<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="Particles &amp;lt;10 μm in diameter are more likely to cause" exact="infection" post="in the lower respiratory tract. Influenza Virus Influenza viruses"/>
 <result pre="humans); geographical region of origin; number of lineage; year of" exact="isolation" post="and, for Influenza A viruses only, HA and NA"/>
 <result pre="young children. Influenza associated encephalopathy can occur due to direct" exact="infection" post="of the central nervous system through viremia and presents"/>
 <result pre="due to influenza occurs either due to the primary virulent" exact="infection" post="or secondary bacterial infection or an increase in physiological"/>
 <result pre="either due to the primary virulent infection or secondary bacterial" exact="infection" post="or an increase in physiological load in a person"/>
 <result pre="the Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) has revolutionised the" exact="diagnosis" post="of influenza. These are highly sensitive and specific and"/>
 <result pre="RT-PCR assays [18]. The major limitation of the NAAT bases" exact="tests" post="is the high cost in resource-limited settings. The cheaper,"/>
 <result pre="high cost in resource-limited settings. The cheaper, Rapid Influenza Diagnostic" exact="tests" post="(RIDT) using monoclonal antibodies are available for point of"/>
 <result pre="point of care. But the results are dependent on the" exact="prevalence" post="of influenza with greater positive predictive value and false"/>
 <result pre="grown in shell vials (Shell Vial Culture). Direct Fluorescent antibody" exact="tests" post="have a reasonable good sensitivity of 60–80% in comparison"/>
 <result pre="and B viruses but cannot be used for subtyping. Serological" exact="tests" post="help to determine presence of influenza specific antibodies following"/>
 <result pre="tests help to determine presence of influenza specific antibodies following" exact="infection" post="and vaccination. Most commonly used are Hemagluttination Inhibition Assay"/>
 <result pre="Virus Neutralisation Assay (VN) and Enzyme Immunoassays (EIA), but these" exact="tests" post="have lower sensitivities compared to NAAT tests. Treatment The"/>
 <result pre="neuroaminase inhibitors like Oseltamivir and Zanamivir are the mainstay for" exact="treatment" post="and help to inhibit the neuraminase which plays a"/>
 <result pre="host cells. Presently Oseltamivir is recommended as the first-line for" exact="treatment" post="of influenza in children. It is less efficacious in"/>
 <result pre="treatment of influenza in children. It is less efficacious in" exact="treatment" post="of Influenza B than A. The indications for initiating"/>
 <result pre="treatment of Influenza B than A. The indications for initiating" exact="treatment" post="are in those children with suspected influenza with high"/>
 <result pre="Dose modification is required in those with renal insufficiency. The" exact="treatment" post="duration is five days, but longer duration can be"/>
 <result pre="recommended since 2006 due to the increased global resistance causing" exact="treatment" post="failures. There are several challenges in the pharmaceutical treatment"/>
 <result pre="causing treatment failures. There are several challenges in the pharmaceutical" exact="treatment" post="of influenza. Varying efficacy of the antiviral drugs, increasing"/>
 <result pre="resistance because of suboptimal dosing during prophylaxis or disruption in" exact="treatment" post="during viral replication [20]. Baloxavir Marboxil was approved by"/>
 <result pre="9 y and under with Oseltamivir-resistant influenza A (H1N1) virus" exact="infection" post="[23]. Combination therapy is also being evaluated for treatment"/>
 <result pre="virus infection [23]. Combination therapy is also being evaluated for" exact="treatment" post="of severe influenza strains which have likely susceptibility to"/>
 <result pre="of sub therapeutic dosing of the antiviral in case the" exact="infection" post="is established. Chemoprophylaxis is best offered to children above"/>
 <result pre="is recommended for chemoprophylaxis when indicated. Early initiation of empiric" exact="treatment" post="for contacts on development of fever or respiratory symptoms"/>
 <result pre="vaccination of health care workers is critical for protection and" exact="infection" post="control. Cough and sneezing etiquettes and hand hygiene are"/>
 <result pre="etiquettes and hand hygiene are important for control of influenza" exact="infection" post="both in the community and the health care settings."/>
 <result pre="the patient are also considered infectious as indirect transmission through" exact="contact" post="can also occur. In health care settings, patients can"/>
 <result pre="which is to be notified of any case of human" exact="infection" post="due to a new Influenza A virus subtype within"/>
 <result pre="Microbiol201941328133610.1038/s41564-019-0447-031110359 17.MageeHGoldmanRDViral myositis in childrenCan Fam Physician20176336536828500193 18.VemulaSVZhaoJLiuJWangXBiswasSHewlettICurrent approaches for" exact="diagnosis" post="of influenza virus infections in humansViruses.201689610.3390/v804009627077877 19.HaydenFDeveloping new antiviral"/>
 <result pre="Dis2019251969197210.3201/eid2510.19060731287050 23.SugayaNOhashiYLong-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as" exact="treatment" post="for children with influenza virus infectionAntimicrob Agents Chemother2010542575258210.1128/AAC.01755-0920368393 24.HouserKSubbaraoKInfluenza"/>
</results>
